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Urinary tract infections are among the most
common infectious diseases in humans.
Today, resistance to nearly all antimicrobial classes is dramati-
cally growing, and extremely drug-resistant or even pan-drug
resistant pathogens are increasingly isolated around the world.
It is foreseen that in the next decades the world will be facing a
major medical emergency generated by the rapid spread of
pathogens carrying resistance determinants of unprecedented
power. Carbapenemase-producing Enterobacteriaceae, mul-
tidrug-resistant Enterococci and fluoroquinolone resistance
determinants in both Gram-negative and Gram-positive
uropathogens are among the greatest emergencies. In this arti-
cle, the major emerging threats of particular interest to urolo-
gists are reviewed, worldwide resistance trends are illustrated,
and novel and older – but still active – recommended drugs are
summarized.
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EMERGING RESISTANCE THREATS
In 2013, the Centers for Disease Control and Prevention
(USA) included carbapenem-resistant Enterobacteriaceae
(CREB) among the three microorganisms posing an
urgent threat to public health, due to the extensive
resistance shown by these pathogens to a wide array of
antibacterial agents, and to the very high mortality rates
reported in patients with bloodstream infections caused
by organisms like carbapenem-resistant KP. 
Several international programs are now aimed at foster-
ing research, development and awareness about the
threat of pathogen resistance. Pivotal European trials are
for example EURECA (European prospective cohort study
on Enterobacteriaeae Showing Resistance to Carbapenems),
and REVISIT (Revisiting serious bacterial infection with
innovation), promoted in the frame of the European
COMBACTE-CARE project, an initiative of the com-
bacte.com collaboration.
Carbapenem resistance
For several decades, extended-spectrum beta-lactamases
(ESBL) of TEM and SHV lineage, conferring resistance
to a variety of penicillins and third-generation
cephalosporins, have represented a worrisome problem
for physicians treating patients affected by infectious dis-
eases. In these cases, carbapenem therapy was a useful
therapeutic resource against ESBL-producing pathogens.
However, today the usefulness of carbapenems is
decreasing rapidly, and the global spread of carbapene-
mase-producing Enterobacteriaceae (the etiological
agents of lung, soft tissue and urinary tract infections)
has undoubtedly become the most important threat in
the field of infectious diseases. The speed of such spread
is alarming: for example, whereas in 2009 the spread of
the Klebsiella pneumoniae carbapenemase (KPC) in the
USA was classified as ‘sporadic’ in half of the federal
states and ‘less than sporadic’ in the remaining states (1),
in 2014 the entire USA territory has been defined as
affected by an ‘endemic’ presence of KPC (2).
The concern raised by this mounting trend is due to the
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INTRODUCTION
Urinary tract infections (UTIs) are among the most com-
mon bacterial-borne diseases in humans. Although anti-
bacterial agents have been the mainstay of treatment for
UTIs for decades, today routine antibiotic therapy is seri-
ously threatened by worldwide outbursts of infections
involving multidrug-resistant (MDR), extremely drug-resist-
ant (XDR) or even pan drug-resistant pathogens. Gram-
negative Enterobacteriaceae like Klebsiella pneumoniae (KP)
and Escherichia coli (EC), and Gram-positive cocci like
Enterococcus faecalis and Enterococcus faecium are at the
same time the most common uropathogens and the bac-
teria carrying the most powerful resistance determinants. 
On the basis of a general assessment of the major resistance
threats, the present review will focus on worldwide sus-
ceptibility trends resulting from large international surveil-
lance studies, and will present some available therapeutic
options -either novel or old but still effective- for the man-
agement of resistant infections of urological interest.
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fact that the spectrum of enzymatic activity of carbapene-
mases is not restricted to drugs like imipenem, ertapenem,
meropenem or doripenem, but
extends to almost all beta-lactams.
Moreover, resistance to carbapen-
ems and other beta-lactams is in
most cases facilitated by horizon-




which often confer multidrug-
resistant, extensively drug-resistant
or even pan drug-resistant proper-
ties to pathogens.
K. pneumoniae is the most preva-
lent pathogen among carbapen-
em-resistant Enterobacteriaceae
according to a recent surveillance
report by the European Centre for
Disease Prevention and Control (3).
Infection with carbapenemase-pro-
ducing KP (CPKP) can double the
mortality rate of affected patients
(from 21% to 42%, all infections),
and can triplicate the mortality of
non-intensive care patients with
UTIs from 13% to 43% in intensive
care unit (ICU) cases (4).
The carbapenemases that have
been characterized so far belong to
all four Ambler classes of beta-lac-
tamases (Table 1). Among the
enzymes of concern for urologists,
the class-A, plasmid-borne K. pneu-
moniae serine carbapenemase (KPC)
is today the most common trans-
missible resistance determinant in
Enterobacteriaceae. KPC includes
more than 20 variants (the most
prevalent being KPC-2 and -3),
who can hydrolyze virtually all
beta-lactam agents including car-
bapenems, penicillins, broad spec-
trum cephalosporins and mono -
bactams. KPCs are only weakly
inhibited by clavulanate and
tazobactam (1, 5), and the encod-
ing blaKPC gene, predominantly
present in IncF plasmids (with FIIK
replicons, and often associated
with a Tn4401 trasposon-like
structure), is very often co-
expressed with cotrimoxazole, flu-
oroquinolone and aminoglycoside
resistance determinants (6). 
Notably, today KPC is no longer
exclusively expressed in KP (main-
ly the ST258 strain) or other CREB,
but is also found in other species
such as Pseudomonas aeruginosa (7).
The SME enzyme also belongs to
class-A carbapenemases, but at present is isolated less fre-
quently than KPC, being in almost all cases restricted
Table 1. 
Carbapenem resistance determinants in pathogens involved in UTIs. 
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to the Serratia marcescens species, a member of the
Enterobacteriaceae family (8).
Class B metallo beta-lactamases/carbapenemases (MBLs)
require zinc for their catalytic activity. These enzymes
are expressed in Enterobacteriaceae but also in P. aerugi-
nosa, and can hydrolyze carbapenems, penicillins and
cephalosporins, but not monobactams. Importantly,
MBLs are not affected by beta-lactamase inhibitors. 
The most powerful and most diffuse MBLs are the New
Delhi MBL (NDM), the Verona-Integron-Encoded MBL
(VIM) and the IMP imipenemase (9). The blaNDM gene
variants are harbored by a variety of broad-host-range
Inc plasmids like IncA/C, IncF, IncR, IncN, IncM, IncX,
which are in turn expressed within various pathogen iso-
lates, including the highly prevalent ST11 KP clone.
Pathogens harboring the NDM are often residually sus-
ceptible to a single last-resort agent like polymixin E,
since NDM is very frequently co-expressed with other
carbapenemases (OXA-48, VIM and/or KPC) and with
multiple resistance determinants such as ESBL, AmpC
beta-lactamases, aminoglycoside-modifying enzymes,
fluoroquinolone resistance enzymes (e.g., Qnr),
macrolide esterases, as well as determinants conferring
resistance to trimethoprim-sulphametoxazole.
Among class C beta-lactamases, the CMY enzymes (e.g.,
ACT-1, CMY-1, CMY-2, and CMY-4, often transferred
via pYMG plasmids) were originally expressed in
Enterobacter spp. but now are being carried by several
other Enterobacteriaceae, including KP (CMY-10). ACT-1
and CMY-1 show moderate carbapenemase activity, are
not significantly inhibited by clavulanic acid, and high-
level resistance to carbapenems is often the result of
combined drug hydrolysis and impaired drug perme-
ability (e.g., involving OmpK35/36 porins) (10, 11).
Class D OXA beta-lactamases can efficiently hydrolyze
penicillins like oxacillin. Some OXA enzymes, such as
OXA-23, OXA-48, OXA-51 and OXA-58, carried mainly
by highly transferable IncL group plasmids like pOXA-
48a, have a weak carbapenemase activity. Nevertheless,
in pathogens like ST-11 KP, high-MIC carbapenem
resistance may result from the concomitant activity of
efflux pumps or low-permeability porins (12).
As far as carbapenem-resistance in Gram-positive
pathogens is concerned, three mechanisms of reduced
beta-lactam susceptibility have been reported in
Enterococci: (i) beta-lactamase production as well as (ii)
overproduction or (iii) inactivation (by point-mutation)
of penicillin-binding proteins like PBP4 or PBP5.
Notably, carbapenem resistance is mainly caused by
point-mutations in PBP4. For example, resistance to
faropenem in E. faecalis is due to decreased affinity of the
drug for PBP4, due to the acquisition of one or two point
mutations in the PBP4-encoding gene (13).
Plasmid-mediated fluoroquinolone resistance
Plasmid mediated fluoroquinolone resistance (PMQR) is
increasing to the point that international guidelines no
longer recommend drugs like ciprofloxacin, ofloxacin or
levofloxacin as first-choice agents for treatment of uri-
nary tract infections, when resistance is assessed in at
least 10% of pathogen isolates (14, 15).
Fluoroquinolones (FQ) inhibit the activity of bacterial
gyrase and topoisomerase IV in Gram-negative and -pos-
itive pathogens. Mutations occurring in the quinolone
resistance determining regions of genes encoding these
type II topoisomerases (e.g., in gyrA, gyrB, parC or parE
subunits) are the most common chromosomal determi-
nants of FQ resistance (16). For example, in Enterococci
resistance to fluoroquinolones is mainly caused by muta-
tions in the GyrA and ParC genes in gyrase and topoiso-
merase IV, respectively (17). Other mechanisms of resist-
ance to FQ are the qepA-encoded efflux pumps, the
OqxAB-encoded efflux pumps -very common in plas-
mids carried by K. penumoniae-, the qnr-encoded pro-
teins, impeding the interaction of FQ with DNA gyrase,
and a mutant aminoglycosyde acetyl-transferase (aac
(6’)-Ib-cr) which acetylates the piperazine ring of FQ like
norfloxacin and ciprofloxacin (18-21). 
Determinants of PMQR are horizontally transferable. For
example, qnrA1, A3, A6, B2, B4, B6 and B10 are associat-
ed with the mobilizing element insertion sequence ISCR,
whereas qnrB1 and B20 are associated with IS26 and
Orf1005. The aac (6’)-Ib-cr enzyme-encoding gene is
often found in association with qnrB and blaCTX in a cas-
sette within an IS26 transposon. In addition, qepA and
OqxAB are also often mobilized by IS26 transposons (22).
Polymyxin resistance
Polymyxins (polymyxin B and colistin/polymyxin E) are
antibiotics produced by the Gram-positive species
Paenibacillus polymyxa. The plasmidic mcr-1 colistin
resistance gene, expressed in Klebsiella spp. and other
Enterobacteriaceae, encodes for a phosphatidy lethano -
lamine transferase enzyme, lessening the affinity of colistin
towards the lipid-A on bacterial cell membranes via enzy-
matic modification (23). This resistance determinant, rap-
idly spreading worldwide (24), represents a major threat
since polymyxins are considered last-resource antibiotics
against CREB.
Glycopeptide resistance
Together with Enterobacteriaceae, Enterococci are the most
common etiological determinants of urinary tract infec-
tions. Acquired resistance to glycopeptide antibiotics in
Enterococci is given by five gene clusters: vanA, vanB,
vanD, vanE and vanG, leading to the expression of pepti-
doglycal pentapeptide precursors (PPP) characterized by
poor affinity for vancomycin and other glycopeptides.
Interestingly, vanA Enterococci are resistant to the last-
generation glycopeptide dalbavancin but are susceptible
to oritavancin, possibily due to the unique dual mecha-
nism of action of the latter (25). Horizontal transfer of Van
genes may occur via Tn-1546 transposons, which are
found in conjugative and non-conjugative plasmids (26). 
WORLDWIDE RESISTANCE TRENDS
Beta-lactam antibiotic resistance
Information about worldwide trends in pathogen resist-
ance is not frequently published, due to the fact that
global epidemiological studies are difficult to perform,
and most studies focus on a single nation or region.
Nevertheless, quality works like for example the 2016
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systematic review by Lee et al. (27), or some global sur-
veillance studies, which are occasionally performed, give
access to evidence concerning global trends of pathogen
chemoresistance.
The Study to Monitor Antimicrobial Resistance Trends
(SMART) is among the largest global surveillance pro-
grams aimed at monitoring longitudinal antimicrobial
resistance patterns worldwide. Over 200,000 clinical sam-
ples have been collected since 2002 from patients with
complicated intra-abdominal infections, whereas isolates
from patients with UTIs have been acquired since 2009.
Among other surveillance actions, susceptibility testing to
12 commonly used antibacterial agents has been per-
formed in different regions of the world. One-hundred
ninety-four hospital sites in countries located within the
macro-regions of Asia/Pacific, Latin America, Middle
East/Africa, North America, and Europe have taken part in
the project. Within the SMART program, the ESKAPE
group of pathogens (Enterococcus spp, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa and Enterobacter spp.) is of main
interest to urologists and accounts for the vast majority of
resistance encountered in nosocomial settings.
Global trends. Data from the SMART project provide an
excellent overview of global resistance trends for
uropathogens. In the frame of SMART, the 2009-2010
susceptibility analysis of E. coli isolates from UTI speci-
mens of hospitalized patients in countries worldwide
showed an overall 17.9% prevalence of extended-spec-
trum beta lactamase (ESBL) resistance determinants (28),
whose rate varied depending on the region considered
(Asia/Pacific, 27.7%, Latin America, 23.3%, Europe, 18.8%,
Middle East/Africa, 16.2%, Northern America, 7.4%). 
Only imipenem and ertapenem demonstrated > 90%
susceptibility in ESBL-positive E. coli at that time (99.7%
and 98% isolates susceptible, respectively), whereas sus-
ceptibility to amikacin and piperacillin-tazobactam was
lower (87.1% and 84.4%, respectively). The least active
agents were ampicillin-sulbactam, all cephalosporins
except cefoxitin, and the fluoroquinolones (28). In the
discussion of their data, Hoban et al. emphasized the rel-
evance of intermediate susceptibility in the treatment of
UTIs, as certain antibacterial agents concentrate physio-
logically in the urine (28). This suggests that in specific
infections showing intermediate susceptibility towards
certain agents, high-dose treatment may be attempted in
the absence of more suitable options.
As far as the geographic distribution of carbapenemases
is concerned, the overall mortality due to CREB reported
in studies from Northern America, Southern America,
Europe, and Asia was 33.2%, 46.7%, 50%, and 44.8%,
respectively (all infections) (4).
KP carbapenemases (KPC) are endemic in the USA, China,
Greece, Italy, Poland, Israel, Brazil, Argentina, Colombia
and Taiwan, whereas sporadic spread of KPC-producing
KP has been observed in virtually all Asian, European
and American countries (summarized in: 27).
The New Delhi metallo beta-lactamases (NDM) confer
resistance to most beta-lactams including carbapenems, as
well as co-resistance to aminoglycosides, tetracyclines, flu-
oroquinolones and other antibacterials, due to the comp-
resence of various resistance determinants within the same
mobile genetic elements. NDM are endemic India, Pakistan
and Bangladesh (27). An analysis of the prevalence of NDM
in the in the frame of the SMART program for years 2008-
2012 – published in 2015 – showed that isolates of nine
different species of NDM-expressing Enterobacteriaceae
were disseminated in India, Serbia, the Philippines, Saudi
Arabia, Guatemala, Vietnam and Georgia, and that different
variants of the NDM gene were compresent with CTX-M
cephalosporinases (29). Moreover, Enterobacteriaceae
 producing the VIM and IMP carbapenemases (alone or  co-
expressed) have been found in Greece, Italy, Spain,
the Philippines, Turkey, Australia, Mexico, USA and India,
with most isolates concomitantly nonsusceptible to one
or more agents like ampicillin-sulbactam, ceftriaxone,
cefepime, ceftazidime, piperacillin-tazobactam,
ciprofloxacin, amikacin, tigecycline and colistin (30).
Importantly, KP isolates produced IMP-26 together with
various VIM variants (VIM-1, 5, 26 or 27), whereas E. coli
expressed IMP-1 alone (30). Class-D OXA carbapene-
mases are endemic in India, Turkey, Morocco, Libya, Egypt
and Tunisia, and sporadic spreads have been documented
throughout Europe and the Middle-East (summarized in:
27). OXA enzymes have been recently isolated in all con-
tinents.
Asia-Pacific. In the Asia-Pacific region, 60 centers from
31 countries provided susceptibility data, which were
collected in years 2010-2013 and published in 2016
(31). Uropathogenic E. coli (UPEC) and KP were the most
prevalent isolates. China showed the highest rates of
ESBL, both in UPEC and KP (66.4% in 2010 and 59.9%
in 2013 for UPEC; 60% in 2010 and 54.5% in 2013 for
KP). Besides China, dramatic increases of ESBL-express-
ing UPEC were observed for example in Thailand (54.2%
in 2013 vs. 36.8% in 2010) and Hong Kong (41.7% in
2013 vs. 25% in 2010), while ESBL-KP were substantial-
ly increased in New Zeland (45.5% in 2013 vs. 23.1% in
2010), South Korea (55.6% in 2013 vs. 37.5% in 2010)
and the Philippines (61.3% in 2013 vs. 37.9% in 2010).
In the same region, Jean et al. reported a significant
increase of the annual rates of carbapenemase prevalence
between year 2008 (0.07%) and year 2014 (1.1%), with
the blaNDM-1 allele becoming more prevalent than the
IMP-26 gene (32).
Latin America. In 11 Latin American countries, analysis of
resistance trends in years 2013-2015, published in 2017,
showed that ESBL-positive KP accounted for 46.6% of
UTI isolates, substantially higher than the values assessed
in SMART 2003 (14%). ESBL-positive rates of KP were
higher (52.9%) in isolates from intensive care unit (ICU)
compared to non-ICU patients (44.4%) (33). Ertapenem
and imipenem showed slightly lower rates of resistance,
compared to other beta-lactams (37.4% and 24.1%,
respectively, versus, e.g., > 38% for cephalosporins and
piperacillin-tazobactam). Among other antimicrobials
tested, the aminoglycoside amikacin continues to show
high rates of susceptibility (92.3%) for isolates of KP (33).
Northern America. The SMART program provided 24655
isolates from Europe and North America, obtained from
ICU (17.8%) and NON-ICU (82.2%) wards. Data from
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90 hospitals in Canada, in the USA and in 18 European
countries were collected. By comparing these regions, in
2015 Lob and coworkers found that resistance among
Enterobacteriaceae in Europe was largely driven by KP
expressing high rates of ESBLs (41.2% in intensive care
units; mostly CTX-M) and carbapenemases (13.2%;
mostly KPC and OXA-types). For all Enterobacteriaceae
combined, only ertapenem and amikacin inhibited >
90% of ICU isolates in both regions. In Northern
America, ertapenem, imipenem and amikacin inhibited
> 90% of KP, whereas in Europe only amikacin attained
such levels, according to Lob et al. (34).
In 2016, the same research group also focused on sus-
ceptibility patterns of ESBL in E. coli from UTIs, repre-
senting the 52% of Gram-negative pathogens collected.
A significant increase in ESBL prevalence was seen in the
US (from 7.8% in 2010 to 18.3% in 2014, P < 0.0001),
whereas in Canada an increase from 10.4% to 13.0% was
not statistically significant (35). Moreover, isolates from
hospital-acquired UTIs increased considerably in the US
(9.4% in 2010 to 27.7% in 2014). The steepest increas-
es over the five-year study period were found among US
males (from 7.1% to 26.2%) and older US patients (from
8.8% to 26.6%) (34).
Europe. National surveillance programs worldwide have
reported extensive spreads of carbapenemase-producing
uropathogens. Logan and Weinstein have edited maps
showing the spread of CREB throughout Europe and the
world (6). According to the 2017 survey published by
the European Centre for Disease Prevention and Control
(ECDC), 25% to 50% isolates of KP are carbapenem-
resistant in Italy, Romania and Greece, the latter showing
rates beyond the upper limit (36). In Europe, the diffu-
sion of KPC is ‘endemic’ in Greece, Poland and Italy (1).
From a study involving 3324 non-replicate isolates of
Enterobacteriaceae from Italian hospitals, it was found
that 4.3% of isolates were non-susceptible to carbapen-
ems, K. pneumoniae being the most prevalent carrier of
the blaKPC carbapenemase gene (in 25.1% and 7.7%
inpatients and outpatients, respectively) (37).
A recent ECDC report focusing on Italy, pointed to dra-
matically increasing resistance trends in this country. For
example, the proportion of CPKP blood isolates increased
from 1.3% in 2006 to 33.5% in 2015, whereas combined
resistance to third-generation cephalosporins, fluoro-
quinolones and aminoglycosides increased from 2.8% in
2005 to 29.7% in 2015. However, in E. coli the proportion
of carbapenem-resistant blood isolates remained low:
0.1% in 2007 to 0.2% in 2015, though combined resist-
ance increased from 0.8% in 2002 to 14.6% in 2015 (38). 
In Germany, a very low incidence of carbapenemase-pro-
ducing isolates has been documented, as a multicenter
study published in 2016 demonstrated an incidence of
0.047 cases per 1000 hospital admissions (39). Low
prevalence has also been reported in Belgium, with 3.5% of
Enterobacteriaceae being carbapenem non-susceptible
through expression of OXA-48, OXA-427, KPC and NDM
(40). A steep growth of carbapenem resistance has been
reported in France. The OXA-48 and NDM resistance
determinants increased from 23.1% in 2012 to 36.2% in
2014 (41).
Non-beta-lactam antibiotic resistance
As far as non-beta-lactam antibiotic susceptibility trends
are concerned, certain African countries show dramatic
prevalences of pan-resistant infections. For example, it
has been reported that in Nigeria uropathogenic E. coli
(UPEC) is pan-resistant to cotrimoxazole (100% iso-
lates), and highly resistant to ofloxacin (70%), gen-
tamycin (92%) and tetracycline (88%) (42).
In various Asia-Pacific countries, the SMART program
reported that the rates of susceptibility to levofloxacin
among hospital isolates of E. coli ranged from 83% in
New Zeland, to 39% in Singapore, to 15% in India (cited
in: 43). The overall prevalence of fluoroquinolone resist-
ance in UPEC is dramatically increasing worldwide, with
increasing trends in Brazil (63.53% increase for
ciprofloxacin and 66.50% for norfloxacin from 2010 to
2015)(44), and with values up to 17% in Italy and 38%
in Turkey (summarized in: 45), whereas in the US a 10-
year study reported an increase from 3% to 17% between
2000 and 2010 (46).
In Europe, the areas showing the highest rates of PMQR
are the Mediterranean countries. This distribution
extends to the whole Mediterranean basin, and the affect-
ed countries are Croatia, Slovenia, Greece, Italy, Spain,
France, Morocco, Algeria, Tunisia, Egypt, and Turkey (47,
48). Resistance to cotrimoxazole in community-acquired
UPEC is high in Southern America (64% in Nicaragua and
up to 58% in pediatric cases in Brazil), Turkey (up to
43%) and Greece (27.3%) whereas in the USA a percent-
age of 24.2 has been reported (45). 
The prevalence of vancomycin-resistant Enterococci (VRE)
causing symptomatic or asymptomatic infections in
Europe ranges between 1 and 30%, whereas in the USA,
VRE are about the 30% of all nosocomial isolates (49).
Encouragingly, Toner et al. reported that the proportion
of VRE has remained stable between 2006 (13.9%) and
2014 (11.5%), whereas a worrisome increase of resist-
ance to nitrofurantoin has been documented in frame of
the same study (just above zero in 2005 to over 40% in
2009 to about 20% in 2014). Notably, in that study the
prevalence of vancomycin resistance was substantially
higher in E. faecium (51.2%) compared to E. faecalis
(1.6%)(49).
Despite the data mentioned above, uropathogens world-
wide seem to retain sensitivity against agents like nitrofu-
rantoin and fosfomycin. For example, the prevalence of
resistance to nitrofurantoin in UPEC isolates has been
reported to be 2.9% in Brazil (year 2007, 50), < 2% in
Europe and 1.6 in the US (45, 49, 50). The figures con-
cerning fosfomycin appear to be as low, with a prevalence
in several European countries inferior to 2% (51, 52). 
As far as infections of urological concern in the pediatric
population are concerned, resistance to ciprofloxacin in
E. coli UTIs increased 10-fold between 2002 and 2009
both in young boys and girls, as shown in a study per-
formed in 195 US pediatric hospitals (1% to 10% and
0.6% to 4% of isolates, respectively) (53).
AVAILABLE AND EMERGING THERAPEUTIC STRATEGIES
Few randomized controlled studies concerning novel or
improved therapeutic protocols against drug-resistant
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infections have been performed so far. Thus, the avail-
able evidence is mainly observational and sometimes
limited to case reports. In most cases, studies focusing on
Enterobacteriaceae are based on complicated cases of
pneumonia or bacteremia. Despite these limitations, this
section will focus on selected therapeutic options -novel
or old but still efficacious- for treatment of infections
caused by resistant pathogens of concern to urologists.
Carbapenems
It is known that certain carbapenemase enzymes can
decrease the susceptibility of pathogens to carbapenems
to a limited extent, and PK/PD data suggest that T > MIC
targets can be met with high probability of attainment
with high-dose continuous infusions of carbapenems
(e.g. 6 g/day meropenem) when MICs are ranging
between 4 and 16 mg/L (summarized in: 54). 
These experimental data are encouraging, though experts
suggest that monotherapy with these agents is not advis-
able, and that combination therapy including a carbapen-
em (when MICs are ≤ 8 mg/L) can result in lower mortal-
ity rates (54). importantly, the efficacy of combined ther-
apies including a carbapenem appears to be MIC-depend-
ent, as mortality rates in sepsis patients infected with KPC-
producing KP were up to 35% for MICs > 16 mg/L, but as
low as 13.3% if the MICs of meropenem (2g,  > 3h infu-
sion thrice daily) were below or equal to 4 mg/L (55).
Interestingly, combination of two carbapenems might
become a last-resort regimen for treating pandrug-resist-
ant and colistin-resort KPC-producing KP infections
(bacteremia, pneumonia, and UTIs). The rationale for
such approach is based on the fact that KPC appears to
have higher affinity for ertapenem compared to other
carbapenems. Thus, while KPC would be “engaged” by
ertapenem, a co-administered different carbapenem
could exert its bactericidal activity. Although recent
quality observational data are encouraging (56-58), addi-
tional, adequately powered studies are urgently warrant-
ed. Moreover, such evidence may ideally foster the
development of ertapenem analogues characterized by
higher affinity for KPC compared to the founder com-
pound, in order to optimally exploit such “engagement”
activity on carbapenemases.
Aztreonam
Monobactam therapy may be considered as an option
against Enterobacteriaceae expressing class B or D car-
bapenemases when these determinants are not co-
expressed with class A enzymes, which are able to effi-
ciently hydrolyze aztreonam (59). In all cases, suscepti-
bility testing is necessary, due to variable monobacta-
mase activity shown by different subclasses of class-B
enzymes.
Avibactam
The novel non-beta-lactam beta-lactamase inhibitor
avibactam (Figure 1) has been approved in 2016 in the
European Union for treatment of soft tissue infections,
pneumonia and urinary tract infections in combination
with the third-generation cephalosporin ceftazidime.
Avibactam inhibits a broad spectrum of beta-lactamases
including A-class, C-class and some D-class carbapene-
mases (60). In vitro assessments performed in the frame
of the INFORM global surveillance study demonstrated
that 98% of CREB isolates containing KPC or OXA-48
enzymes were susceptible to this combination, even
when the isolates expressed ESBLs or AmpC enzymes
(61, 62). However, ceftazidime/avibactam was ineffective
against carbapenem-hydrolyzing metallo-beta-lacta-
mases like NDM. 
In vitro activity of this combination was also demon-
strated in the frame of a phase 3 trial involving cef-
tazidime-resistant UTIs (63). Recently, Jayol et al. inves-
tigated the in vitro activity of ceftazidime/avibactam,
alone (for class A and D carbapenemase producers) or in
combination with aztreonam (for class-B carbapenemase
Figure 1. 
Chemical structure of the novel non-beta-lactam  
beta-lactamase inhibitors avibactam, relebactam and
vaborbactam. Structures were drawn using the PubChem
NIH public repository database (93). 
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producers), against a collection of colistin-resistant and
carbapenemase-producing KP isolates (64). 
It was shown that ceftazidime/avibactam was effective
against colistin-resistant and KPC-producing or OXA-
48-producing KP, and was also efficient against KP iso-
lates co-expressing two carbapenemases. Interestingly,
the combination of ceftazidime/avibactam with aztreon-
am was synergic against NDM-producing KP. 
Investigators suggested that such synergic activity could
be explained by the neutralization of the ESBL activity by
avibactam, which can in turn restore the susceptibility of
KP to aztreonam (64). These data warrant urgent clinical
investigation. 
The clinical efficacy of the ceftazidime/avibactam combi-
nation (2g/0.5g, intravenous q8h) was demonstrated by
recent phase 3 studies in patients with complicated
UTIs, including acute pyelonephritis (65, 66). Further
studies are urgently needed to investigate the clinical
cure rates of this combination in UTIs caused by CREB.
Relebactam
The SMART program provided isolates from the USA,
which were used for testing the activity of imipenem
combined with the newly developed, renally excreted
carbapenemase inhibitor relebactam. Relebactam is struc-
turally related to avibactam, differing only by the pres-
ence of an amide functional group bound to a piperidine
ring (Figure 1). For KP, 99% and 96.1% of isolates were
susceptible to imipenem-relebactam and imipenem
alone, respectively, and 74.1% of imipenem-resistant iso-
lates were rendered susceptible to the carbapenem by
addition of relebactam (67). In vitro assays showed that
the combination imipenem/relebactam decreased the
MICs of KPC-producing KP compared to imipenem alone
(MIC50: 0.25/4 mg/L, MIC90: 1/4 mg/L), but was not as
effective against pathogens expressing class D enzymes
(e.g., OXA-48 in KP) (68). To date, phase II clinical trials
have reported that imipenem/relebactam is as effective as
imipenem alone for treatment of complicated UTIs,
including acute pyelonephritis (69).
Imipenem-relebactam is currently investigated in the
frame of phase III clinical trials for the treatment of
imipenem-resistant infections.
Vaborbactam
Vaborbactam (VB) is a boronic acid-based non-beta lac-
tam beta-lactamase inhibitor, registered by FDA in 2017
for therapy of complicated urinary tract infections, com-
bined with meropenem (2g/2g, intravenous q8h, to be
adjusted in patients with renal impairment). Its chemical
structure is not related to the ones of avibactam or rele-
bactam (Figure 1). 
Similar to meropenem, VB is renally excreted, and up to
60% of a dose is found unchanged in the urine within 24
hours. VB inhibits class A beta-lactamases (including
KPC) and class C AmpC β-lactamases. 
The meropenem/VB combination decreases the MICs of
most resistant Enterobacteriaceae (2-fold to > 1024-fold
decrease), though it appears that the addition of VB does
not improve the activity of meropenem against P. aerug-
inosa (70). 
Meropenem/VB is active against CREB isolates and
against Enterobacteriaceae showing multidrug-resistant
and extensively drug-resistant phenotypes (MIC50/90:
0.5/32, 0.03/1, and 0.5/32 mg/L, respectively), though
this drug combination showed limited activity against
isolates expressing metallo-β-lactamases (e.g., NDM-1,
VIM) and oxacillinases (e.g., OXA-48, OXA-163) detect-
ed in Asia-Pacific and in certain European countries (71).
The TANGO-1 phase III clinical trial has reported supe-
riority of meropenem/VB over piperacillin/tazobactam
for the treatment of complicated UTIs, including acute
pyelonephritis (72). The TANGO-2 randomized, open-
label phase III clinical trial of meropenem/VB versus “best
available therapy” in patients with complicated urinary
tract infections, bacteremia or pneumonia, was stopped
early due to a benefit-risk ratio in favor of meropen-
em/VB (73).
Polymyxins
The polymyxin antibiotics colistin (poliymyxin E) and
poliymyxin B have become a mainstay in the treatment
of CREB infections. The EUCAST breakpoint for resist-
ance is 2 mg/L. Recent studies resulted in the recom-
mendation to prescribe high doses of the antibiotic (up
to 10 million international units), divided into twice- or
thrice-daily administrations (74). Importantly, combina-
tion therapy including colistin and rifampin was shown
to be effective against colistin-resistant, KPC-producing
KP (75). Though new polymyxin derivatives with
decreased toxicity are under development, nephrotoxic-
ity occurring in about 40% of cases and neurotoxicity are
limiting factors to the extensive administration of colistin
for treatment of CREB-induced infections. A possible
limiting factor to the full exploitation of polymyxins for
UTIs may also be the limited renal clearance of these
drugs, though pharmacokinetic studies seem to confirm
that the urinary recovery of colistin may be sufficient to
attain concentrations above the MICs shown for example
by XDR P. aeruginosa (76). 
Aminoglycosides
Plazomicin is a novel aminoglycoside ("neoglycoside")
antibiotic closely related to sisomicin and structurally
recalling gentamicin. Its molecular structure was
designed to be resistant against aminoglycoside-modify-
ing enzymes, which are often expressed in CREB isolates
(77). For example, in non-NDM-expressing CREB, the
MICs of plazomicin ranged between > 0.5 and 2 mg/L,
compared to 0.25/ > 256 mg/L and 1/128 mg/L for gen-
tamicin and amikacin, respectively (78).
Three-hundred multidrug resistant ESBL-producing
and/or carbapenemase-producing Enterobacteriaceae iso-
lates from Athens, Greece (a CREB endemic area), most of
which were also resistant to previous generation amino-
glycosides (e.g., MIC50/MIC90 to amikacin = 32/ > 32),
were tested for sensitivity to plazomicin. This novel
aminoglycoside retained activity against all tested isolates
of K. pneumoniae, E. coli, and Enterobacter spp., with
MIC50 and MIC90 of 1 and 2 μg/ml, respectively, irre-
spective of their multidrug-resistant phenotype (79). In
strains of CREB resistant to gentamicin, tobramycin and
amikacin, plazomicin exhibited an MIC range of 0.12-4
mg/L, with MIC50 and MIC90 values of 0.25 and 1 mg/L,
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respectively. Interestingly, in CPKP isolates, synergy was
observed when plazomicin was combined with
meropenem, colistin or fosfomycin, whereas the combi-
nation with tigecycline resulted in indifference (80). 
The safety and efficacy of plazomicin vs. levofloxacin in
treating UTIs was assessed in a phase II comparative
study, which ended in 2012 (81). Microbiological eradi-
cation in the plazomicin group (15 mg/kg) was achieved
in 93.1% of the patients whose baseline urinary
pathogens had a plazomicin MIC of 4 mg/L. 
Microbiological eradication in the group receiving lev-
ofloxacin (750 mg) was achieved in 93.8% (15/16) of
patients with levofloxacin-susceptible baseline urinary
pathogens (MIC = 4 mg/L). The EPIC and CARE phase
III trials, investigating the safety and efficacy of pla-
zomicin in patients with complicated UTIs and other
infections caused by gram-negative pathogens including
CREB, have been concluded but not yet published in the
form of journal articles.
Fosfomycin
Only case reports are available showing the efficacy of
fosfomycin -administered in monotherapy for uncompli-
cated UTIs or combined with colistin against urosepsis-
in infections caused by Enterobacteriaceae expressing
KPC, OXA-48 and NDM carbapenemases (82, 83). Case
reports include accounts of successful combination ther-
apy including dual carbapenem plus oral fosfomycin in
UTIs caused by NDM-expressing Enterobacteriaceae (57).
Such approach is preferable, as the rapid development of
resistance during therapy is a major problem related to
the usage of fosfomycin as single agent (84). 
Intravenous formulations of fosfomycin allow adminis-
tration of high doses of the drug (e.g., 4g q6h), if neces-
sary (85). A small prospective case series including
eleven critically ill ICU patients affected by CPKP bac-
teremia, UTI or pneumonia, was based on administra-
tion of intravenous fosfomycin (2-4g q6h) for about 14
days, combined with colistin (n = 6), gentamicin (n = 3)
or piperacillin/tazobactam (n = 1), based on ascertained
susceptibility. All-cause hospital mortality was 18.2%,
and no infection relapse was observed in enrolled
patients. Intravenous therapy with high-dose fosfomycin
appeared to be well tolerated, without renal or liver func-
tion test abnormalities (86). Further large-scale studies
are warranted to confirm these encouraging safety and
efficacy results.
Oritavancin
Oritavancin is a semi-synthetic lipoglycopeptide, charac-
terized by a threefold mechanism of action: (i) inhibition
of the transglycosylation pathway in the bacterial wall
synthesis, (ii) inhibition of the transpeptidation step by
binding to the peptide bridging cell wall segments and
(iii) cell wall disruption. 
A recent in vitro subset study in the frame of a prevalence
analysis performed on over 140.000 bloodstream isolates
of Enterococci from Europe and the USA demonstrated
that oritavancin was active against vancomycin-resistant E.
faecalis (MIC50/90, 0.25-0.5 mg/L), and showed MIC50,
MIC90 and MIC100 values of 0.03, 0.12 and 0.25 mg/L
against VanA-positive E. faecium, respectively (87). 
Oritavancin is renally and fecally excreted as unmodified
molecule and may represent an interesting agent for treat-
ing complicated UTIs, though such approach would be
off-label, as this drug is approved for the moment only for
Gram-positive skin and skin structure infections.
Fluoroquinolones
Chen et al. have examined in detail how the pharmacoki-
netic-pharmacodynamic properties of fluoroquinolones
could be exploited to design treatment strategies in areas
with high rates of fluoroquinolone resistance (43).
Levofloxacin appears to be a better option compared to
ciprofloxacin, since the excretion of the former is by 87%
renal (ciprofloxacin: 50%), and since efflux pumps like
AcrAB, MdfA and NorE are more active on the latter
(88). Thus, as the bactericidal activity of these agents is
concentration-dependent, the achievement of high peak
urine concentrations as a result of high-dose treatment
with levofloxacin may be the key for eradicating
pathogens showing intermediate FQ resistance levels.
For example, a single 750 mg dose of levofloxacin
achieves a mean urinary Cmax of 620 mg/L, with pro-
longed post-antibiotic effect, compared to 340 mg/L
attained by a standard 500 mg dose (89). Chen et al. also
suggested that in areas with resistance uropathogen rates
> 20%, high-dose levofloxacin might be considered as an
option for UTIs caused by E. coli isolates showing a MIC
≤ 32 mg/L, after taking into consideration the potential
adverse effects of such therapy (43).
The aac (6')-I gene product (AAC) confers to
Enterobacteriaceae resistance to aminoglycoside antibi-
otics through acetylation of specific -NH2 residues at the
level of specific amino sugars. A mutated variant of AAC
(aac (6')-Ib-cr) confers resistance to certain fluoro-
quinolones via acetylation of the (= NH) residue within
the piperazine ring of drugs like ciprofloxacin or nor-
floxacin. This decreases by 4-fold the susceptibility of
pathogens to such drugs (90) and increases by 16 times
the fluoroquinolone mutant prevention concentration in
E. coli (0.2 –> 3.2 mg/L), thus facilitating the survival of
target site mutants (91). Interestingly, FQs like lev-
ofloxacin have a methylated piperazine residue which is
virtually protected from the action of AAC. Thus, if resist-
ance rates caused by the AAC are present or suspected,
levofloxacin, or other "protected" FQs like prulifloxacin or
pefloxacin may be temptatively administered.
Glycylcyclines
Together with colistin, tigecycline is often the only agent
to which CPKP is residually susceptible. However, the
use of this agent for treatment of urological infections is
significantly associated with subsequent development of
resistance, as shown by van Duin and coworkers (OR,
6.13; 95% CI, 1.15-48.65) (92).
CONCLUSIONS
In conclusion, in the next decades the world will be fac-
ing a major medical emergency generated by the rapid
spread of pathogens carrying resistance determinants of
unprecedented power. All medical specialties will be
affected by such spread, including foremostly urology. 
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As far as urinary tract diseases are concerned, we believe
that the old definition of complicated vs uncomplicated
infections should be modified, as any UTI involving car-
bapenemase-expressing uropathogens, or MDR/XDR
uropathogens, should be considered and managed as
complicated conditions.
Urgent containment measures must be put into effect,
with priority given to those areas of the world character-
ized by climatic conditions favoring the seasonal outburst
of infection epidemics, but also by negligent clinical prac-
tice, unprofessional pharmaceutical dispensing, as well as
by poor patient compliance and education. Rigorous
antibiotic stewardship and restriction of novel and old last
resort agents to the sole hospital setting will also con-
tribute to the containment of “superbug” epidemics.
Regretfully, major pharmaceutical companies have aban-
doned research for novel antibacterial agents due to the
little financial reward ensured by drugs which can cure
diseases in a very short time and at the same time may
become rapidly obsolete due to the emerging of
pathogen resistance. 
Nevertheless, public or private research mainly aimed at
discovering new therapies against Gram-negative organ-
isms is of vital importance. Only the future will tell us
who will prevail in the struggle for survival between
humans and bacteria, and ultimately in the war between
the immense resources of human ingenuity and the
immense adaptability of genomes and species.
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